WO2014169817A1 - Composé de phénylalanine ayant un groupe de liaison hétérocyclique azoté, composition pharmaceutique associée, son procédé de préparation et son utilisation - Google Patents
Composé de phénylalanine ayant un groupe de liaison hétérocyclique azoté, composition pharmaceutique associée, son procédé de préparation et son utilisation Download PDFInfo
- Publication number
- WO2014169817A1 WO2014169817A1 PCT/CN2014/075466 CN2014075466W WO2014169817A1 WO 2014169817 A1 WO2014169817 A1 WO 2014169817A1 CN 2014075466 W CN2014075466 W CN 2014075466W WO 2014169817 A1 WO2014169817 A1 WO 2014169817A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- alkyl
- acid
- oxy
- phenyl
- Prior art date
Links
- -1 Phenylalanine compound Chemical class 0.000 title claims abstract description 171
- 229910052757 nitrogen Inorganic materials 0.000 title claims abstract description 28
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title claims description 78
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 title abstract description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 124
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 135
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 132
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 44
- 235000011054 acetic acid Nutrition 0.000 claims description 44
- 238000006243 chemical reaction Methods 0.000 claims description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 22
- 239000008103 glucose Substances 0.000 claims description 22
- 206010012601 diabetes mellitus Diseases 0.000 claims description 21
- 229910052736 halogen Inorganic materials 0.000 claims description 21
- 150000002367 halogens Chemical class 0.000 claims description 21
- 229910052760 oxygen Inorganic materials 0.000 claims description 21
- 125000005842 heteroatom Chemical group 0.000 claims description 20
- 229910052717 sulfur Inorganic materials 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 229940002612 prodrug Drugs 0.000 claims description 14
- 239000000651 prodrug Substances 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 238000005893 bromination reaction Methods 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims description 9
- 125000004043 oxo group Chemical group O=* 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 238000006460 hydrolysis reaction Methods 0.000 claims description 8
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical group CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 6
- 238000006069 Suzuki reaction reaction Methods 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 229940125758 compound 15 Drugs 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 claims description 5
- 229940126657 Compound 17 Drugs 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 230000008878 coupling Effects 0.000 claims description 5
- 238000010168 coupling process Methods 0.000 claims description 5
- 238000005859 coupling reaction Methods 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 235000011167 hydrochloric acid Nutrition 0.000 claims description 5
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 claims description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims description 4
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims description 4
- 125000005605 benzo group Chemical group 0.000 claims description 4
- 229940125797 compound 12 Drugs 0.000 claims description 4
- 229940126543 compound 14 Drugs 0.000 claims description 4
- 229940126142 compound 16 Drugs 0.000 claims description 4
- 229940125810 compound 20 Drugs 0.000 claims description 4
- 229940126086 compound 21 Drugs 0.000 claims description 4
- 238000005886 esterification reaction Methods 0.000 claims description 4
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims description 4
- 239000003223 protective agent Substances 0.000 claims description 4
- 238000006722 reduction reaction Methods 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 3
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 claims description 3
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 3
- 238000005727 Friedel-Crafts reaction Methods 0.000 claims description 3
- 238000007341 Heck reaction Methods 0.000 claims description 3
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- FXXACINHVKSMDR-UHFFFAOYSA-N acetyl bromide Chemical compound CC(Br)=O FXXACINHVKSMDR-UHFFFAOYSA-N 0.000 claims description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 2
- 239000012346 acetyl chloride Substances 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 229940125773 compound 10 Drugs 0.000 claims description 2
- 230000032050 esterification Effects 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 238000005984 hydrogenation reaction Methods 0.000 claims description 2
- 150000007529 inorganic bases Chemical class 0.000 claims description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 239000000543 intermediate Substances 0.000 claims 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 5
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 208000018914 glucose metabolism disease Diseases 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 125000004266 aziridin-1-yl group Chemical group [H]C1([H])N(*)C1([H])[H] 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 22
- 210000004369 blood Anatomy 0.000 abstract description 22
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 11
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 abstract description 10
- 229930186217 Glycolipid Natural products 0.000 abstract description 10
- 208000030159 metabolic disease Diseases 0.000 abstract description 2
- 230000002503 metabolic effect Effects 0.000 abstract 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 140
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 108
- 235000019260 propionic acid Nutrition 0.000 description 98
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 80
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 77
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 67
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 67
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 66
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 235000019439 ethyl acetate Nutrition 0.000 description 23
- 239000002904 solvent Substances 0.000 description 22
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 14
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 14
- 239000012046 mixed solvent Substances 0.000 description 14
- 239000001301 oxygen Substances 0.000 description 14
- 239000007787 solid Substances 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- 239000003054 catalyst Substances 0.000 description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 239000003208 petroleum Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 235000011181 potassium carbonates Nutrition 0.000 description 8
- 101000912510 Homo sapiens Free fatty acid receptor 1 Proteins 0.000 description 7
- 125000006612 decyloxy group Chemical group 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- BZCALJIHZVNMGJ-HSZRJFAPSA-N Fasiglifam Chemical compound CC1=CC(OCCCS(C)(=O)=O)=CC(C)=C1C1=CC=CC(COC=2C=C3OC[C@@H](CC(O)=O)C3=CC=2)=C1 BZCALJIHZVNMGJ-HSZRJFAPSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000003914 insulin secretion Effects 0.000 description 5
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 5
- IIGNZLVHOZEOPV-UHFFFAOYSA-N 3-Methoxybenzyl alcohol Chemical compound COC1=CC=CC(CO)=C1 IIGNZLVHOZEOPV-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- 102000052080 human FFAR1 Human genes 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- OGFAWKRXZLGJSK-UHFFFAOYSA-N 1-(2,4-dihydroxyphenyl)-2-(4-nitrophenyl)ethanone Chemical compound OC1=CC(O)=CC=C1C(=O)CC1=CC=C([N+]([O-])=O)C=C1 OGFAWKRXZLGJSK-UHFFFAOYSA-N 0.000 description 3
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- LXGQHDUCNDGTDB-PAMNCVQHSA-N [2-[(8s,9r,10s,13s,14s,16s,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate;[2-[(8s,9r,10s,13s,14s,16s,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11, Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)CC2O.C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)CC2O LXGQHDUCNDGTDB-PAMNCVQHSA-N 0.000 description 3
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- OXKUGIFNIUUKAW-UHFFFAOYSA-N n,n-dimethylformamide;hydrazine Chemical compound NN.CN(C)C=O OXKUGIFNIUUKAW-UHFFFAOYSA-N 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- UXCDUFKZSUBXGM-UHFFFAOYSA-N phosphoric tribromide Chemical compound BrP(Br)(Br)=O UXCDUFKZSUBXGM-UHFFFAOYSA-N 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 239000001294 propane Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- HFRXJVQOXRXOPP-UHFFFAOYSA-N thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 description 3
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229960001701 chloroform Drugs 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
- 229910000105 potassium hydride Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 102000027257 transmembrane receptors Human genes 0.000 description 2
- 108091008578 transmembrane receptors Proteins 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- BZXQRXJJJUZZAJ-UHFFFAOYSA-N (2,4,6-trimethylphenyl)boronic acid Chemical compound CC1=CC(C)=C(B(O)O)C(C)=C1 BZXQRXJJJUZZAJ-UHFFFAOYSA-N 0.000 description 1
- CXDPUSMFYPQXCV-UHFFFAOYSA-N (2,6-dichlorophenyl)boronic acid Chemical compound OB(O)C1=C(Cl)C=CC=C1Cl CXDPUSMFYPQXCV-UHFFFAOYSA-N 0.000 description 1
- CKISAVBWCHIXGH-UHFFFAOYSA-N (2,6-dicyclopropylphenyl)boronic acid Chemical compound OB(O)C1=C(C2CC2)C=CC=C1C1CC1 CKISAVBWCHIXGH-UHFFFAOYSA-N 0.000 description 1
- GOMOOVJOVBVJLF-UHFFFAOYSA-N (2,6-diethylphenyl)boronic acid Chemical compound CCC1=CC=CC(CC)=C1B(O)O GOMOOVJOVBVJLF-UHFFFAOYSA-N 0.000 description 1
- DBZAICSEFBVFHL-UHFFFAOYSA-N (2,6-difluorophenyl)boronic acid Chemical compound OB(O)C1=C(F)C=CC=C1F DBZAICSEFBVFHL-UHFFFAOYSA-N 0.000 description 1
- BKWVXPCYDRURMK-UHFFFAOYSA-N (2,6-dimethoxyphenyl)boronic acid Chemical compound COC1=CC=CC(OC)=C1B(O)O BKWVXPCYDRURMK-UHFFFAOYSA-N 0.000 description 1
- SFHGWHQCLNBFJY-UHFFFAOYSA-N (2,6-dimethyl-4-sulfanylphenyl)boronic acid Chemical compound CC1=C(C(=CC(=C1)S)C)B(O)O SFHGWHQCLNBFJY-UHFFFAOYSA-N 0.000 description 1
- DIRRKLFMHQUJCM-UHFFFAOYSA-N (2-aminophenyl)boronic acid Chemical compound NC1=CC=CC=C1B(O)O DIRRKLFMHQUJCM-UHFFFAOYSA-N 0.000 description 1
- QSSPYZOSTJDTTL-UHFFFAOYSA-N (2-ethylphenyl)boronic acid Chemical compound CCC1=CC=CC=C1B(O)O QSSPYZOSTJDTTL-UHFFFAOYSA-N 0.000 description 1
- YDMRDHQUQIVWBE-UHFFFAOYSA-N (2-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1O YDMRDHQUQIVWBE-UHFFFAOYSA-N 0.000 description 1
- ROEQGIFOWRQYHD-UHFFFAOYSA-N (2-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC=C1B(O)O ROEQGIFOWRQYHD-UHFFFAOYSA-N 0.000 description 1
- NSJVYHOPHZMZPN-UHFFFAOYSA-N (2-methylphenyl)boronic acid Chemical compound CC1=CC=CC=C1B(O)O NSJVYHOPHZMZPN-UHFFFAOYSA-N 0.000 description 1
- SFUIGUOONHIVLG-UHFFFAOYSA-N (2-nitrophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1[N+]([O-])=O SFUIGUOONHIVLG-UHFFFAOYSA-N 0.000 description 1
- KTZUVUWIBZMHMC-UHFFFAOYSA-N (2-propan-2-ylphenyl)boronic acid Chemical compound CC(C)C1=CC=CC=C1B(O)O KTZUVUWIBZMHMC-UHFFFAOYSA-N 0.000 description 1
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 1
- OGYKUMRPICACAC-UHFFFAOYSA-N (4-bromo-2,6-dimethylphenyl)boronic acid Chemical compound CC1=CC(Br)=CC(C)=C1B(O)O OGYKUMRPICACAC-UHFFFAOYSA-N 0.000 description 1
- FVASMUNXBUYNIX-UHFFFAOYSA-N (4-chloro-2,6-dimethylphenyl)boronic acid Chemical compound CC1=CC(Cl)=CC(C)=C1B(O)O FVASMUNXBUYNIX-UHFFFAOYSA-N 0.000 description 1
- GNTWJIXJCKRFJD-UHFFFAOYSA-N (4-fluoro-2,6-dimethylphenyl)boronic acid Chemical compound CC1=CC(F)=CC(C)=C1B(O)O GNTWJIXJCKRFJD-UHFFFAOYSA-N 0.000 description 1
- UOSSBXMFWPYHEF-UHFFFAOYSA-N (4-methoxy-2,6-dimethylphenyl)boronic acid Chemical compound COC1=CC(C)=C(B(O)O)C(C)=C1 UOSSBXMFWPYHEF-UHFFFAOYSA-N 0.000 description 1
- BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 1
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 1
- YBFVJRKIDLRWRV-UHFFFAOYSA-N 2-[2-(trifluoromethyl)phenyl]pyridine Chemical compound FC(F)(F)C1=CC=CC=C1C1=CC=CC=N1 YBFVJRKIDLRWRV-UHFFFAOYSA-N 0.000 description 1
- DGENZVKCTGIDRZ-UHFFFAOYSA-N 3-[4-[(3-phenoxyphenyl)methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=CC(OC=2C=CC=CC=2)=C1 DGENZVKCTGIDRZ-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- VOMMPWVMVDGZEM-UHFFFAOYSA-N 6-bromo-1h-pyridin-2-one Chemical compound OC1=CC=CC(Br)=N1 VOMMPWVMVDGZEM-UHFFFAOYSA-N 0.000 description 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 1
- FWEOQOXTVHGIFQ-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid Chemical compound C=12C(S(=O)(=O)O)=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-N 0.000 description 1
- 0 Bc1c(*)cc(*)cc1* Chemical compound Bc1c(*)cc(*)cc1* 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- PGMKVZRHEHASRS-UHFFFAOYSA-N C(C)C1=C(C(=CC=C1)CC)C1=NC=CC=C1 Chemical compound C(C)C1=C(C(=CC=C1)CC)C1=NC=CC=C1 PGMKVZRHEHASRS-UHFFFAOYSA-N 0.000 description 1
- FPNFPYDOHODLBL-UHFFFAOYSA-N CN(C=O)C.[Os] Chemical compound CN(C=O)C.[Os] FPNFPYDOHODLBL-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical group [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- RZALGKILTARQHB-UHFFFAOYSA-N Cc(cc(cc1C)F)c1-c1nc(OCc2ccc(CCC(O)=O)cc2)ccc1 Chemical compound Cc(cc(cc1C)F)c1-c1nc(OCc2ccc(CCC(O)=O)cc2)ccc1 RZALGKILTARQHB-UHFFFAOYSA-N 0.000 description 1
- IOTCOTWDHMFSAF-UHFFFAOYSA-N Cc(cc(cc1C)N)c1-c1nc(OCc2ccc(CCC(O)=O)cc2)ccc1 Chemical compound Cc(cc(cc1C)N)c1-c1nc(OCc2ccc(CCC(O)=O)cc2)ccc1 IOTCOTWDHMFSAF-UHFFFAOYSA-N 0.000 description 1
- PWJNXUMORPAZGH-UHFFFAOYSA-N Cc(cc(cc1C)OCCCCS(C)(=O)=O)c1-c1nc(OCc2cc(OCC3CC(O)=O)c3cc2)ccc1 Chemical compound Cc(cc(cc1C)OCCCCS(C)(=O)=O)c1-c1nc(OCc2cc(OCC3CC(O)=O)c3cc2)ccc1 PWJNXUMORPAZGH-UHFFFAOYSA-N 0.000 description 1
- QLMNZDWIBFHJIJ-UHFFFAOYSA-N Cc(cc(cc1C)OCCCS(C)(=O)=O)c1-c1nc(OCc2ccc(C(CC(O)=O)CS3)c3c2)ccc1 Chemical compound Cc(cc(cc1C)OCCCS(C)(=O)=O)c1-c1nc(OCc2ccc(C(CC(O)=O)CS3)c3c2)ccc1 QLMNZDWIBFHJIJ-UHFFFAOYSA-N 0.000 description 1
- ZRKBVLOBYLMIQM-UHFFFAOYSA-N Cc(cc(cc1C)OCCN(C)C)c1-c1nc(OCc2ccc(CCC(O)=O)c(F)c2)ccc1 Chemical compound Cc(cc(cc1C)OCCN(C)C)c1-c1nc(OCc2ccc(CCC(O)=O)c(F)c2)ccc1 ZRKBVLOBYLMIQM-UHFFFAOYSA-N 0.000 description 1
- JDISSIULIZLTNM-UHFFFAOYSA-N Cc(cc(cc1C)OCCN2CCNCC2)c1-c1nc(OCc2cc(OCC3CC(O)=O)c3cc2)ccc1 Chemical compound Cc(cc(cc1C)OCCN2CCNCC2)c1-c1nc(OCc2cc(OCC3CC(O)=O)c3cc2)ccc1 JDISSIULIZLTNM-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 229940125827 GPR40 agonist Drugs 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- RKHGTDJJQAVFBK-UHFFFAOYSA-N [2-(2-methylpropyl)phenyl]boronic acid Chemical compound CC(C)CC1=CC=CC=C1B(O)O RKHGTDJJQAVFBK-UHFFFAOYSA-N 0.000 description 1
- XSZUHKRFUPVGIM-UHFFFAOYSA-N [2-(methylamino)phenyl]boronic acid Chemical compound CNC1=CC=CC=C1B(O)O XSZUHKRFUPVGIM-UHFFFAOYSA-N 0.000 description 1
- JNSBEPKGFVENFS-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC=C1C(F)(F)F JNSBEPKGFVENFS-UHFFFAOYSA-N 0.000 description 1
- USEHFBIGOATLIA-UHFFFAOYSA-N [2-methyl-4-(trifluoromethyl)phenyl]boronic acid Chemical compound CC1=CC(C(F)(F)F)=CC=C1B(O)O USEHFBIGOATLIA-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 1
- 235000012733 azorubine Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- YSVBPNGJESBVRM-UHFFFAOYSA-L disodium;4-[(1-oxido-4-sulfonaphthalen-2-yl)diazenyl]naphthalene-1-sulfonate Chemical compound [Na+].[Na+].C1=CC=C2C(N=NC3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)O)=CC=C(S([O-])(=O)=O)C2=C1 YSVBPNGJESBVRM-UHFFFAOYSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- MJTBOJTZBTVRNH-UHFFFAOYSA-N ethyl 2-(6-diphenylphosphanylcyclohexa-2,4-dien-1-ylidene)acetate Chemical compound CCOC(=O)C=C1C=CC=CC1P(C=1C=CC=CC=1)C1=CC=CC=C1 MJTBOJTZBTVRNH-UHFFFAOYSA-N 0.000 description 1
- HFMNGULPSOGRFM-UHFFFAOYSA-N ethyl 3-[4-(bromomethyl)phenyl]propanoate Chemical compound CCOC(=O)CCC1=CC=C(CBr)C=C1 HFMNGULPSOGRFM-UHFFFAOYSA-N 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- FUJCRWPEOMXPAD-UHFFFAOYSA-N lithium oxide Chemical compound [Li+].[Li+].[O-2] FUJCRWPEOMXPAD-UHFFFAOYSA-N 0.000 description 1
- 229910001947 lithium oxide Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical compound CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- VEDDBHYQWFOITD-UHFFFAOYSA-N para-bromobenzyl alcohol Chemical compound OCC1=CC=C(Br)C=C1 VEDDBHYQWFOITD-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- CHWRSCGUEQEHOH-UHFFFAOYSA-N potassium oxide Chemical compound [O-2].[K+].[K+] CHWRSCGUEQEHOH-UHFFFAOYSA-N 0.000 description 1
- 229910001950 potassium oxide Inorganic materials 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- SYXYWTXQFUUWLP-UHFFFAOYSA-N sodium;butan-1-olate Chemical compound [Na+].CCCC[O-] SYXYWTXQFUUWLP-UHFFFAOYSA-N 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 description 1
- 235000012756 tartrazine Nutrition 0.000 description 1
- 229960000943 tartrazine Drugs 0.000 description 1
- 239000004149 tartrazine Substances 0.000 description 1
- 238000006177 thiolation reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- the present invention relates to the field of pharmacy, and in particular to a phenylpropionic acid compound containing a nitrogen-containing heterocyclic link, and a medicament thereof a physiologically acceptable salt, stereoisomer or prodrug molecule thereof, pharmaceutical composition thereof, preparation method, and use thereof in the preparation of a medicament for treating diabetes and disorders of glycolipid metabolism, especially in the preparation of type II diabetes Use of the drug.
- the above compounds have a remarkable function of lowering blood sugar and regulating glycolipid metabolism activity.
- Background Art It is well known that diabetes is a chronic disease that is the third most serious threat to human health after cancer and cardiovascular and cerebrovascular diseases.
- Type I diabetes is characterized by a lack of insulin secretion called insulin-dependent diabetes mellitus (IDDM), which is caused by its inability to use insulin effectively, called non-insulin-dependent diabetes mellitus (NIDDM).
- IDDM insulin-dependent diabetes mellitus
- NIDDM non-insulin-dependent diabetes mellitus
- Type II diabetes accounts for more than 90% of the global diabetes population.
- the pathogenesis of type 2 diabetes mellitus is complicated, and its basic characteristics are that skeletal muscle, liver, fat and other tissues are resistant to insulin.
- islet ⁇ cells can compensate insulin secretion to compensate for the deficiency of insulin, thus maintaining normal blood sugar levels.
- the islet ⁇ -cell insulin secretion function is insufficient, and the patient's compensatory mechanism collapses, resulting in abnormally elevated blood glucose levels, which in turn leads to the formation of type 2 diabetes in the body.
- GTP-binding protein coupling receptor 40 (GP 40) is a seven-pass transmembrane receptor. It is abundantly expressed in islets and is also expressed in the intestinal system. Current research suggests that this transmembrane receptor may be associated with certain cancers, neurological diseases, and metabolic diseases, especially diabetes. Studies have found that various forms of free fatty acid (FFA) are natural ligands for GPR40. FFA amplifies glucose-stimulated insulin secretion by activating GPR40 on the islet beta cell membrane. Given that GPR40 receptor agonists have a glucose-dependent advantage in promoting insulin secretion, they are potential targets for the treatment of diabetes.
- FFA free fatty acid
- the present invention is directed to compounds having the structure of Formula I below which are distinct from the structures of the reported compounds.
- the compound of the present invention has a remarkable function of lowering blood sugar and regulating glycolipid metabolism activity, and is a novel type of GPR40 agonist.
- An object of the present invention is to provide a phenylpropionic acid compound represented by the following formula I, or a pharmaceutically acceptable salt thereof, or an enantiomer thereof, a racemate and a mixture thereof, or a stereoisomer thereof Body, or its prodrug molecule.
- Another object of the present invention is to provide a process for the preparation of a phenylpropionic acid compound of the formula I.
- Another object of the present invention is to provide a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of a phenylpropionic acid compound selected from the formula I, a pharmaceutically acceptable salt thereof, an enantiomer thereof, and the like Racemization One or more of a mixture, a mixture thereof, a stereoisomer thereof and a prodrug molecule thereof, and a pharmaceutically acceptable excipient.
- a further object of the present invention is to provide a phenylpropionic acid compound selected from the formula I, a pharmaceutically acceptable salt thereof, an enantiomer thereof, a racemate and a mixture thereof, and stereoisomers thereof Use of one or more of a body and a prodrug molecule thereof for the manufacture of a medicament for the treatment of diabetes and disorders of glycolipid metabolism.
- It is still another object of the present invention to provide a method of treating diabetes and disorders of glycolipid metabolism comprising administering to a subject in need of such treatment a phenylpropionic acid compound selected from Formula I or a pharmaceutically acceptable compound thereof.
- a phenylpropionic acid compound selected from Formula I or a pharmaceutically acceptable compound thereof.
- One aspect provides a phenylpropionic acid compound of the formula I:
- R n R 2 are each independently selected from the group consisting of H, hydroxy, halogen, nitro, dC ⁇ fluorenyl, halo dC ⁇ fluorenyl, dC ⁇ decyloxy, halo dC ⁇ decyloxy, C 3 -C 1() a cycloalkyl group and a 3- to 10-membered heterocyclic group containing 1 to 3 hetero atoms selected from S, 0 and N; preferably selected from the group consisting of H, hydroxy, halogen, nitro, CC 6 ⁇ ⁇ CrC 6 C ⁇ - C 6 3 ⁇ 43 ⁇ 4 , ⁇ ⁇ CC 6 C 3 -C 8 i groups and 3 to 10 membered heterocyclic groups containing at least one nitrogen atom; more preferably each independently selected from H, hydroxy, halogen, nitro, C r C 4 -mercapto, halo C r C 4 fluorenyl, C r C 4 decyloxy,
- R 3 is selected from the group consisting of H; halogen; carboxy; C r C 2 () fluorenyl; halogenated C r C 2 () fluorenyl; -O a ; -N( a ) S0 2 b , -NR ab; -N ( a ) C(0) b ; -C(0)NR ab ; -S0 2 a ; -S b ; selected from C d .
- ⁇ Preferably selected from H ; halogen; carboxy; C r C 6 fluorenyl; halogenated C r C 6 fluorenyl; -OR a; -N( a )S0 2 b ; -NR ab; -N( a )C(0 b ; -C(0)NR ab ; -S0 2 a ; -S b ; selected from CC 4 decyloxy, C 3 -C 8 cyclodecyl, -SR C , -S0 2 R c , -NR Cd or substituted C substituted by a substituent in a 3-6 membered heterocyclic group containing 1 to 3 heteroatoms selected from 0, S and N substituted by dC 4 fluorenyl, hydroxy or oxo group r C 6 embankment group; and the embankment with a C r C 4 group, 3 - 8 cycloalkyl group embankment, -SR
- R b are each independently selected from the group consisting of H, C r C 6 fluorenyl, C 3 -C 8 cyclodecyl and unsubstituted or substituted by C r C 6 fluorenyl or oxo group and selected from 0, S and N 3-8 membered heterocyclic groups of 1 to 3 heteroatoms; preferably each independently selected from H, C r C 4 fluorenyl, C 3 -C 6 cyclodecyl and unsubstituted or C r C 3 fluorenyl Or a methoxy group-substituted 3-6 membered heterocyclic group containing 1 to 3 heteroatoms selected from the group consisting of 0, S and N;
- R c and R d are each independently selected from H, C r C 6 fluorenyl and 3- substituted or substituted by ( ⁇ - 3 fluorenyl) containing 1 to 3 heteroatoms selected from 0, S and N 8-membered heterocyclic group; preferably each independently selected from H, C r C 3 fluorenyl and unsubstituted or substituted by C r C 3 fluorenyl containing 1 to 3 heteroatoms selected from 0, S and N 3-6 membered heterocyclic group;
- R 4 is selected from the group consisting of H, hydroxy, halogen, dC fluorenyl and halogenated dC fluorenyl; preferably H, hydroxy, halogen, C r C 6 fluorenyl and halogenated C r C 6 fluorenyl,
- R 5 is selected from the group consisting of H, halogen and dC fluorenyl; preferably H, halogen and C r C 6 fluorenyl; or R 4 together with the carbon atom attached thereto and benzene ring together form a benzo 5-8 membered heterocyclic ring group, containing heterocycle selected from 0, N and S, 1 to 3 hetero atoms, and said heterocyclic group is unsubstituted or substituted alkyl with C r C 6; R 4 and preferably together with it, and The linked carbon atom together with the benzene ring form a benzo 5-membered heterocyclic group containing one to two heteroatoms selected from the group consisting of 0, N and S. And not substituted or substituted by C r C 3 thiol; further preferably, R 4 and associated with it
- Carbon atoms form together with the benzene ring or.
- phenylpropionic acid compound of the formula I of the present invention has a structure represented by the following formula II or formula III:
- R 6 is H or C r C 6 fluorenyl, and in Formula III, when Z is 0 or S, R 6 is absent.
- halogen includes fluorine, chlorine, bromine and iodine.
- halo refers to a single or multiple halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine.
- d-o fluorenyl refers to a straight or branched fluorenyl group having from 1 to 20 carbon atoms in the main chain, and includes, without limitation, methyl, ethyl, n-propyl, isopropyl, n-butyl Base, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, octyl, decyl, undecyl, fluorenyl, tetradecyl, sixteenth, seventeen , 18 courtyards, 20 courtyards, etc.
- C C6 yard base and "Ci-Gt yard base” have similar meanings.
- d-omethoxy refers to a straight or branched decyloxy group having from 1 to 20 carbon atoms in the main chain, and includes, without limitation, methoxy, ethoxy, n-propoxy, and iso Propyloxy, butoxy, pentyloxy, hexyloxy, octyloxy, decyloxy, undecyloxy, dodecyloxy, tetradecyloxy, hexadecanyloxy, seventeen Oxygen, ten hospital oxygen, twenty hospital oxygen, etc.
- CK "Ci-C 6 methoxy" and "C r C 4 methoxy” have similar meanings.
- C 3 -C 1 () cyclodecyl refers to a cyclic fluorenyl group having 3 to 10 carbon atoms in the ring, including, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl. And cycloheptyl; the terms “C 3 -C 8 cyclodecyl” and “C 3 -C 6 cyclodecyl” have similar meanings.
- 3-8 membered heterocyclic group means a non-aromatic ring group having 3-8 atoms on the ring containing at least one atom selected from the group consisting of N, 0 and S atoms, such as an epoxy group, a pyrrolidinyl group, Morpholinyl and the like; the terms “5-8 membered heterocyclic group” and “3-6 membered heterocyclic group” have similar meanings.
- pharmaceutically acceptable salt in the present invention means a compound represented by the formula I according to the present invention and a mineral acid such as phosphoric acid, sulfuric acid or hydrochloric acid, or acetic acid, tartaric acid, citric acid, malic acid or fumaric acid.
- An organic acid, or a salt formed by an acidic amino acid such as aspartic acid or glutamic acid, or a salt formed with an inorganic base after forming an ester or an amide with the above-mentioned acid, such as sodium, potassium, calcium, aluminum salt and ammonium salt.
- the compound is preferably selected from the following compounds:
- Step 1 R 4 -substituted p-bromobenzyl alcohol 1 and ethyl acrylate 2 are subjected to Heck reaction to obtain intermediate 3, and the double bond is reduced to obtain intermediate 4, and then bromination is carried out to convert benzyl alcohol into benzyl bromide to obtain intermediate
- the Heck reaction can be carried out, for example, in the presence of a palladium metal catalyst such as palladium acetate, tetrakis(triphenylphosphine)palladium or bis(triphenylphosphine)palladium dichloride, for example, ruthenium, osmium-dimethylformamide.
- the double bond reduction reaction can be carried out using, for example, hydrogen gas in a solvent such as ethyl acetate, butyl acetate, methanol, ethanol or n-propanol in the presence of, for example, a palladium carbon composite catalyst.
- the bromination reaction can be carried out using a brominating agent such as phosphorus tribromide, phosphorus pentabromide, phosphorus oxybromide or dibromosulfoxide in a solvent such as acetonitrile, dichloromethane or diethyl ether;
- Step 2 Intermediate 5 and substrate 6 are subjected to nucleophilic substitution reaction to obtain intermediate 7;
- the nucleophilic substitution reaction can be, for example, potassium carbonate, cesium carbonate, sodium hydride, potassium hydride, potassium t-butoxide, tert-butyl
- a base such as sodium acetate or sodium hydroxide
- a solvent such as acetonitrile, hydrazine, hydrazine-dimethylformamide or tetrahydrofuran;
- Step 3 Intermediate 7 and The intermediate 8 is obtained by Suzuki reaction coupling, and the intermediate 8 is subjected to hydrolysis reaction to obtain the product 9;
- the Suzuki reaction may be, for example, a mixed solvent of toluene/acetonitrile/water in the presence of a catalyst such as tetrakis(triphenylphosphine)palladium, bis(triphenylphosphine)palladium dichloride, palladium acetate or palladium carbon composite, a mixed solvent of toluene/ethanol/water, a mixed solvent of acetonitrile/water or a mixed solvent of ethanol/water; and the hydrolysis reaction of the intermediate 8 may be a base such as potassium hydroxide, sodium hydroxide or lithium hydroxide.
- a solvent such as an acetonitrile/water mixed solvent, a methanol/water mixed solvent or an ethanol/water mixed solvent;
- Step 1 Compound 17 (wherein Z is 0 or S, R 6 is absent) or 20 (wherein Z is N, R 6 is H or C r C 6 fluorenyl) and substrate 6 is subjected to nucleophilic substitution reaction
- Compound 21 is obtained, and the nucleophilic substitution reaction can be carried out, for example, in the presence of a catalyst such as potassium carbonate, cesium carbonate, sodium hydride, potassium t-butoxide or sodium t-butoxide in, for example, acetonitrile, acetone, ethyl acetate, tetrahydrofuran or hydrazine.
- a catalyst such as potassium carbonate, cesium carbonate, sodium hydride, potassium t-butoxide or sodium t-butoxide in, for example, acetonitrile, acetone, ethyl acetate, tetrahydrofuran or hydrazine.
- a catalyst such as potassium carbonate, cesium carbonate, sodium
- Step 2 Compound 21 and The intermediate 22 is obtained by Suzuki reaction coupling, and the intermediate 22 is subjected to hydrolysis reaction to obtain the product 23;
- the Suzuki reaction can be, for example, tetrakis(triphenylphosphine)palladium, bis(triphenylphosphine)palladium dichloride,
- a catalyst such as palladium acetate or palladium carbon composite
- a mixed solvent such as toluene/acetonitrile/water, a mixed solvent of toluene/ethanol/water, a mixed solvent of acetonitrile/water or a mixed solvent of ethanol/water
- the hydrolysis can be carried out in the presence of a base such as potassium hydroxide, sodium hydroxide or lithium hydroxide in a solvent such as an acetonitrile/water mixed solvent, a methanol/water mixed solvent or an ethanol/water mixed solvent.
- the compounds 17 and 20 can be prepared by the following method:
- Step 1 The hydroxyl group of the compound 10 is protected with a protective agent to obtain a compound 11, and then subjected to a Friedel-Craft reaction with chloroacetyl chloride to obtain a compound 12;
- the protective agent may be acetic anhydride, acetyl chloride or acetyl bromide, and the reaction for protecting the hydroxyl group may be, for example, dichloro in the presence of a catalyst such as triethylamine, diisopropylethylamine or 4-dimethylaminopyridine.
- the Friedel-Craft reaction can be, for example, in the presence of a catalyst such as aluminum trichloride, zinc dichloride or boron trifluoride diethyl ether solution; In a solvent such as dichloromethane, trichloromethane or diethyl ether;
- Step 2 Compound 12 is subjected to intramolecular nucleophilic substitution reaction to obtain compound 13, and then subjected to a fitting reaction with a Witting reagent to obtain a compound 14;
- the intramolecular nucleophilic substitution reaction can be, for example, sodium acetate, potassium acetate, potassium carbonate, tert-butyl
- a base such as potassium alkoxide or sodium t-butoxide
- a solvent such as methanol, ethanol or acetonitrile
- the witting reaction can be carried out in a solvent such as toluene, benzene or xylene.
- Step 3 Compound 14 is subjected to hydrogenation reduction to obtain compound 15.
- compound 15 is hydrolyzed to obtain compound 16, and compound 16 is subjected to bromination reaction, followed by dropwise addition.
- Anhydrous ethanol is subjected to an esterification reaction to obtain a compound 17;
- the reduction reaction can be carried out in the presence of a catalyst such as palladium on carbon in a solvent such as methanol, ethanol or ethyl acetate;
- the hydrolysis reaction can be, for example, sodium hydroxide or hydrogen
- the bromination reaction may be, for example, phosphorus tribromide, phosphorus pentabromide, phosphorus oxybromide Or in the presence of a brominating agent such as dibromosulfoxide in a solvent such as acetonitrile or ethyl acetate;
- the bromination reaction may be, for example, phosphorus tribromide, phosphorus pentabromide, phosphorus oxybromide or dibromosulfoxide.
- a brominating agent in a solvent such as acetonitrile or ethyl acetate;
- ⁇ is 0, S or N, and R 7 is C r C 6 fluorenyl
- a pharmaceutical composition comprising a therapeutically effective amount of a phenylpropionic acid compound selected from the above formula I, an enantiomer thereof, a racemate thereof And one or more of a mixture thereof and a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable excipient.
- the pharmaceutical composition can be used to treat diabetes or disorders of glycolipid metabolism.
- a further aspect of the invention provides a phenylpropionic acid compound selected from the formula I, an enantiomer thereof, a racemate, and mixtures thereof, stereoisomers thereof, prodrug molecules thereof, and Use of one or more of the pharmaceutically acceptable salts for the manufacture of a medicament for the treatment of diabetes or disorders of glycolipid metabolism.
- a method of treating diabetes or a disorder of glycolipid metabolism comprising administering to a patient in need thereof a therapeutically effective amount of a phenylpropionic acid compound selected from the present invention, which is aligned One or more of the isomers, racemates and mixtures thereof, stereoisomers thereof, prodrug molecules thereof, and pharmaceutically acceptable salts thereof, or a pharmaceutical composition according to the present invention.
- the nuclear magnetic resonance spectrum was recorded with a Bmker AMX-400, Gemini-300 or AMX-600 nuclear magnetic resonance instrument, and the unit of chemical shift ⁇ was ppm.
- the specific optical rotation was measured by a Perkin-Elmer Model 241, and the microwave used was a CEM-discovery microwave reactor. All reaction solvents were purified according to a conventional method. Column chromatography with silica gel (200-300 mesh) is produced by Qingdao Ocean Chemical Branch. Thin layer chromatography was performed using the GF254 high efficiency plate for the Yantai Institute of Chemical Industry. Preparative thin-layer chromatography plates were prepared by themselves.
- the stationary phase was prepared by GF254 (HG/T2354-92) silica gel and sodium carboxymethylcellulose (800-1200), respectively, Qingdao Ocean Chemical Co., Ltd. and China Pharmaceutical (Group). Shanghai Chemical Reagent Company produces. All solvents were analytically pure reagents, and the reagents used were purchased from Sinopharm Chemical Reagent Co., Ltd. Color development was carried out by means of iodine or ultraviolet fluorescence. The organic solvent was distilled off under reduced pressure in a rotary evaporator.
- the compound 3-(4-((6-(2-methylphenyl)pyridin-2-yl)) was prepared in a similar manner to Example 4 except that 2-methylphenylboronic acid was used instead of phenylboronic acid. Oxygen)methylene)phenyl)propionic acid.
- the compound 3-(4-((6-(4-methylphenyl)pyridin-2-yl)oxy) was prepared in a similar manner to Example 4 except that p-methylbenzeneboronic acid was used instead of phenylboronic acid. Methylene)phenyl)propionic acid.
- the compound 3-(4-((6-(2-ethylphenyl)pyridin-2-yl)oxy) was prepared in a similar manner to Example 4 except that 2-ethylbenzeneboronic acid was used instead of phenylboronic acid. Methylene)phenyl)propionic acid.
- the compound 3-(4-((6-(2-isopropylphenyl)pyridin-2-yl) was prepared in a similar manner to Example 4 except that 2-isopropylbenzeneboronic acid was used instead of phenylboronic acid. Oxy)methylene)phenyl)propionic acid.
- the compound 3-(4-((6-(2-tert-butylphenyl)pyridin-2-yl) was prepared in a similar manner to Example 4 except that 2-isobutylbenzeneboronic acid was used instead of phenylboronic acid. Oxy)methylene)phenyl)propionic acid.
- the compound 3-(4-((6-(2-nitrophenyl)pyridin-2-yl) was prepared in a similar manner to that shown in Example 4 except that 2-nitrophenylboronic acid was used instead of phenylboronic acid. Oxy)methylene)phenyl)propionic acid.
- the compound 3-(4-((6-(2-hydroxyphenyl)pyridin-2-yl)oxy)) was prepared in a similar manner to Example 4 except that 2-hydroxyphenylboronic acid was used instead of phenylboronic acid. Methyl)phenyl)propionic acid.
- the compound 3-(4-((6-(2-(trifluoromethyl)phenyl)pyridine) was prepared in a similar manner to Example 4 except that 2-trifluoromethylbenzeneboronic acid was used instead of phenylboronic acid. -2-yl)oxy)methylene)phenyl)propanoic acid.
- the compound 3-(4-((6-(2-methoxyphenyl)pyridin-2-yl) was prepared in a similar manner to Example 4 except that 2-methoxyphenylboronic acid was used instead of phenylboronic acid. Oxy)methylene)phenyl)propionic acid.
- the compound 3-(4-((6-(2-methylaminophenyl)pyridin-2-yl)) was prepared in a similar manner to Example 4 except that 2-methylaminobenzeneboronic acid was used instead of phenylboronic acid. Oxygen)methylene)phenyl)propionic acid.
- the compound 3-(4-((6-(2,6-diethylphenyl)pyridine) was prepared in a similar manner to Example 4 except that 2,6-diethylbenzeneboronic acid was used instead of phenylboronic acid. -2-yl)oxy)methylene)phenyl)propanoic acid.
- the compound 3-(4-((6-(2,6-dimethoxyphenyl)) was prepared in a similar manner to Example 4 except that 2,6-dimethoxyphenylboronic acid was used instead of phenylboronic acid. Pyridin-2-yl)oxy)methylene)phenyl)propanoic acid.
- the compound 3-(4-((6-(2,6-difluorophenyl)pyridine-2) was prepared in a similar manner to Example 4 except that 2,6-difluorophenylboronic acid was used instead of phenylboronic acid. -yl)oxy)methylene)phenyl)propanoic acid.
- the compound 3-(4-((6-(2,6-methyl-)-) was prepared in a similar manner to Example 4 except that 2,6-dimethyl-4-hydroxybenzeneboronic acid was used instead of phenylboronic acid. 4-Hydroxyphenyl)pyridinyloxy)methylene)phenyl)propanoic acid.
- the compound 3-(4-((6-(2,4,6-trimethyl)) was prepared in a similar manner to Example 4 except that 2,4,6-trimethylphenylboronic acid was used instead of phenylboronic acid. Phenyl)pyridin-2-yl)oxy)methylene)phenyl)propanoic acid.
- the compound 3-(4-((6-(4-amino-2,6)) was obtained in a similar manner to Example 4 except that 2,6-dimethyl-4-aminophenylboronic acid was used instead of phenylboronic acid. -Dimethylphenyl)pyridin-2-yl)oxy)methylene)phenyl)propionic acid.
- the compound 3-(4-((6-(4-carboxy-2,6)) was obtained in a similar manner to Example 4 except that 2,6-dimethyl-4-carboxylic acid phenylboronic acid was used instead of phenylboronic acid. -Dimethylphenyl)pyridin-2-yl)oxy)methylene)phenyl)propionic acid.
- the compound 3-(4-((6-(4-amido)-) was prepared in a similar manner to Example 4 except that 2,6-dimethyl-4-carbamoylbenzeneboronic acid was used instead of phenylboronic acid. 2,6-Dimethylphenyl)pyridin-2-yl)oxy)methylene)phenyl)propanoic acid.
- the compound 3-(4-((6-(4-fluoro-2,6)) was prepared in a similar manner to Example 4 except that 2,6-dimethyl-4-fluorobenzeneboronic acid was used instead of phenylboronic acid.
- 2,6-dimethyl-4-fluorobenzeneboronic acid was used instead of phenylboronic acid.
- the compound 3-(4-((6-(4-methoxy)) was prepared in a similar manner to Example 4 except that 2,6-dimethyl-4-methoxyphenylboronic acid was used instead of phenylboronic acid.
- 2,6-dimethyl-4-methoxyphenylboronic acid was used instead of phenylboronic acid.
- -2,6-Dimethylphenyl)pyridin-2-yl)oxy)methylene)phenyl)propanoic acid was prepared in a similar manner to Example 4 except that 2,6-dimethyl-4-methoxyphenylboronic acid was used instead of phenylboronic acid.
- a compound 3-K 6-(4-methylthio-2,6- was obtained in a similar manner to Example 4 except that 2,6-dimethyl-4-methylmercaptophenylboronic acid was used instead of phenylboronic acid.
- a compound 3-(4-:(:6-(2,6-dimethyl) was obtained in a similar manner to Example 4 except that 2,6-dimethyl-4-methylaminobenzeneboronic acid was used instead of phenylboronic acid.
- a compound 3-(4-:(6-(2,) was obtained in a similar manner to Example 4 except that 2,6-dimethyl-4-(dimethylamino:)benzeneboronic acid was used instead of phenylboronic acid. 6-Dimethyl-4-dimethylaminophenyl:)pyridin-2-yl)oxy)methylene)phenyl)propanoic acid.
- a compound 3-(4-:(:6) was obtained in a similar manner to Example 4 except that 2,6-dimethyl-4-(methylsulfonylmethyl:)aminobenzeneboronic acid was used instead of phenylboronic acid.
- 2,6-dimethyl-4-(methylsulfonylmethyl:)aminobenzeneboronic acid was used instead of phenylboronic acid.
- -(2,6-Dimethyl-4-(N-methylmethanesulfonamide)phenyl)pyridin-2-yl)oxy)methylene)phenyl)propanoic acid was used instead of phenylboronic acid.
- Example 38 3-(4-((6-(2,6-Dimethylphenyl)pyridin-2-yl)oxy)methylene)-2-chlorophenyl)propanoic acid (Compound HYH- 035)
- Example 40 3 -( 4 -(( 6- ( 2 , 6 -Dimethyl- 4 -hydroxyphenyl)pyridine- 2 -yl)oxy)methylene) -2 -chlorophenyl)propanoic acid (Compound HYH-037
- the 85 mg sample obtained above was dissolved in a mixture of 8 mL of acetonitrile and 2 mL of water, and 10 mg of lithium hydroxide was added thereto, and reacted at 40 ° C for 4 hours, cooled, adjusted to pH 2-3 with 1 M hydrochloric acid, and 20 mL of saturated brine was added thereto.
- the organic layer was combined and dried over anhydrous sodium sulfate and filtered to give 3-(4-(2, 6-dimethyl-4-(2-(methylsulfonyl)) 68 mg of ethoxy)phenyl)pyridin-2-yl)oxy)methylene)phenyl)propanoic acid as a white solid, yield 84%.
- Example 42 3-(4-((6-(2,6-Dimethyl-4-(2-(ethanesulfonyl)ethoxy)phenyl)pyridin-2-yl)oxy)) Preparation of phenyl)propionic acid (compound HYH-039)
- the compound 3-(4-(:6-) was obtained in a similar manner to Example 41 except that 2-ethylsulfonylethyl p-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester.
- a compound 3-(4-:(:6) was obtained in a similar manner to Example 41 except that 3-methanesulfonylpropyl p-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester.
- the compound 3-(4-:(:6) was obtained in a similar manner to Example 41 except that 3-ethylsulfonylpropyl p-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester.
- 3-ethylsulfonylpropyl p-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester.
- -(2,6-Dimethyl-4-(3-(ethylsulfonyl)propoxy)phenyl)pyridin-2-yl)oxy)methylene)phenyl)propanoic acid was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester.
- a compound 3-K was prepared in a similar manner to Example 41 except that 2-methoxyethyl-p-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester.
- a compound 3-(4-: was obtained in a similar manner to that shown in Example 41 except that 2-ethoxyethyl p-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester. : 6-(4-(2-ethoxyethoxy)-2,6-dimethylphenyl)pyridin-2-yl)oxy)methylene)phenyl)propanoic acid.
- Compound 3-(4-) was prepared in a similar manner to Example 42 except that 2-dimethyl:) amino: ethyl p-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester. (((6-(4-(2-Dimethylaminoethoxy)-2,6-dimethylphenyl)pyridin-2-yl)oxy)methylene)phenyl)propanoic acid.
- a compound 3-(4-X6) was obtained in a similar manner to Example 41 except that 3-(diethylamino)propyl p-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester.
- 3-(diethylamino)propyl p-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester.
- -(4-p-Diethylaminopropoxy)-2,6-dimethylphenyl)pyridin-2-yl)oxy)methylene)phenyl)propanoic acid was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester.
- Example 41 A method similar to that of Example 41 was used except that 1,1-dioxotetrahydro-2/7-thiopyran-4-p-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester.
- the compound 3-K 6-(2,6- was obtained in a similar manner to Example 41 except that 2-morpholine ethyl p-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester. Dimethyl-4-(2-morpholineethoxy)phenyl)pyridin-2-yl)oxy)methylene)phenyl)propanoic acid.
- Step 2 Dissolve 9.7 g of 3-methoxybenzyl alcohol acetate in 40 mL of anhydrous dichloromethane, add 12.8 mL of chloroacetyl chloride dropwise at room temperature, and then add 23.6 g of anhydrous chlorinated in multiple batches. Aluminum was then refluxed for 16 hours.
- Step 5 Dissolve 1.15 g of 6-hydroxymethyl acetate-benzofuran-3-yl:ethyl acetate into 20 mL of ethyl acetate, add 10% Pd/C 100 mg, hydrogen at atmospheric pressure The atmosphere was allowed to stand overnight at room temperature, and the diatomaceous earth was passed over to remove palladium carbon, and the filtrate was concentrated and separated on a silica gel column to obtain ethyl (6-hydroxymethyl acetate-2,3-dihydrobenzofuran-3-yl)acetate.
- Step 6 Dissolve 6. Og of 6-hydroxymethyl acetate-2,3-dihydrobenzofuran-3-yl:)acetate in 20 mL of acetonitrile, add 4 mL of water, and add 100 mg of hydrogen with stirring. Lithium oxide was reacted at 50 ° C for 4 hours, cooled to room temperature, 50 mL of water was added, and extracted with dichloromethane for 3 times. The combined organic layers were dried over anhydrous sodium sulfate to give (6-hydroxymethyl-2,3- 0.68 g of dihydrobenzofuran-3-yl)acetic acid was an off-white solid with a yield of 91%.
- Step 7 0.65 g of (6-hydroxymethyl-2,3-dihydrobenzofuran-3-yl)acetic acid was added to a 10 mL round bottom flask, and 1 mL of phosphorus tribromide was added dropwise, and the reaction was carried out at 80 ° C. After 2 hours, the reaction solution was cooled to 0 ° C, and 1.0 mL of anhydrous ethanol was added dropwise, and the reaction mixture was poured into 100 mL of ice water, and the mixture was extracted three times with ethyl acetate.
- Step 1 0.5 g of (6-hydroxymethyl-2,3-dihydrobenzofuran-3-yl)acetate and 0.29 g of 2-bromo-6-hydroxypyridine were dissolved in 20 mL of acetonitrile, and added to 0.35. g potassium carbonate, then reacted at 60 ° C for 3 hours, cooled to room temperature, and concentrated on a column to give 2-(6-((6-bromopyridin-2-yl)oxy)methylene)-2,3 Ethyl dihydrobenzofuran-3-yl)acetate 0.58 g, yield 88%.
- Step 2 Weigh 100.Omg of compound 2-(6-((6-bromopyridin-2-yl)oxy)methylene)-2,3-dihydrobenzofuran-3-yl)acetic acid Ester, 65.0 mg 4-hydroxy-2,6-dimethylphenylboronic acid, 15.0 mg of tetrakis(triphenylphosphine)palladium and 75.0 mg of potassium carbonate were added to a 10 mL microwave reactor special tube, and 2.0 mL of toluene, 0.4 mL was added. Ethanol and 0.4 mL of water were replaced with nitrogen for 3 times, and then placed in a CEM microwave reactor at 120 ° C for 30 minutes.
- Step 3 and Step 4 In addition to using 2-(6-((6-(4-hydroxy-2,6-dimethylphenyl)pyridin-2-yl)oxy)methylene)-2, 3-(4-((6-(2,6-dimethyl-4-hydroxyphenyl)pyridin-2-yl)oxy)) In the same manner as in Example 42 except that methyl (ethyl)phenyl)propanoate was obtained, 2-(6-((6-(2,6-dimethyl-4-(2-) Methanesulfonyl)ethoxy)phenyl)pyridin-2-yl)oxy)methylene)-2,3-dihydrobenzofuran-3-yl)acetic acid.
- Example 67 2-(6-((6-(2,6-Dimethyl-4-(4-(methylsulfonyl)butoxy)phenyl)pyridin-2-yl)oxy)) Preparation of bis(2,3-dihydrobenzofurazol-3-yl)acetic acid (compound HYH-063)
- Compound 2-(6-:(:6) was obtained in a similar manner to Example 65 except that 4-methanesulfonylbutyl p-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester.
- Example 69 2-(6-((6-(2,6-Dimethyl-4-(2-methoxyethoxy)phenyl)pyridin-2-yl)oxy)methylene) Preparation of -2,3-dihydrobenzofuran-3-yl)acetic acid (compound HYH-065)
- Compound 2-(6-X6-(2) was obtained in a similar manner to Example 65 except that 2-methoxyethyl-p-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester.
- Example 70 2-(6-((6-(2,6-Dimethyl-4-(3-methoxypropoxy)phenyl)pyridin-2-yl)oxy)methylene) Preparation of -2,3-dihydrobenzofurazol-3-yl)acetic acid (compound HYH-066)
- Compound 2-(6-X6-(2) was obtained in a similar manner to Example 65 except that 3-methoxypropyl-p-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester. ,6-Dimethyl-4-P-methoxypropoxy)phenyl)pyridin-2-yl)oxy)methylene)-2,3-dihydrobenzofuran-3-yl)acetic acid.
- Example 71 2-(6-((6-(2,6-Dimethyl-4-(2-dimethylaminoethoxy)phenyl)pyridin-2-yl)oxy)methylene) Preparation of -2,3-dihydrobenzofurazol-3-yl)acetic acid (compound HYH-067)
- a compound 2-(6-(:6-) was obtained in a similar manner to Example 65 except that 2-dimethylaminoethyl-p-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester.
- Compound 2-(6-(:6-) was obtained in a similar manner to Example 65 except that 3-dimethylaminopropyl-p-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester. (2,6-Dimethyl-4-P-dimethylaminopropoxy)phenyl)pyridin-2-yl)oxy)methylene)-2,3-dihydrobenzofuran-3-yl) Acetic acid.
- Example 73 2-(6-((6-(2,6-Dimethyl-4-((tetrahydro-2-pyridin-4-yl)oxy)phenyl)pyridin-2-yl)) Preparation of Oxygen) Methylene)-2,3-Dihydrobenzofurazol-3-yl)acetic Acid (Compound HYH-069)
- Compound 2-(6- was obtained in a similar manner to Example 65 except that tetrahydro-2/7-pyran-4-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester.
- Compound 2-(6- was prepared in a similar manner to Example 65 except that tetrahydro-2/7-thiopyran-4-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester. :(:6-(2,6-Dimethyl-4tetrahydro-2/7-thiopyran-4-yl)oxy)phenyl)pyridin-2-yl)oxy)methylene)-2, 3-Dihydrobenzofuran-3-yl)acetic acid.
- the compound 2-(6-X6-(2,6-) was obtained in a similar manner to Example 65 except that the piperidin-4-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester.
- the compound 2-(6-X6-() was prepared in a similar manner to Example 65 except that 1-methylpiperidine-4-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester. 2,6-Dimethyl-4-G-methylpiperidin-4-yl)oxy)phenyl)pyridin-2-yl)oxy)methylene)-2,3-dihydrobenzofuran- 3-yl)acetic acid.
- Example 77 2-(6-((6-(2,6-Dimethyl-4-((1,1-dioxotetrahydro-2-thio-4-yl)oxy)benzene) Preparation of pyridin-2-yl)oxy)methylene)-2,3-dihydrobenzofuran-3-yl)acetic acid (compound HYH-073)
- Example 65 A method similar to that of Example 65 was carried out except that 1,1-dioxotetrahydro-2/7-thiopyran-4-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester.
- Example 78 2-(6-((6-(4-(4-hydroxy-1,1-dioxotetrahydro-2H-thyl-4-yl)methoxy)-2,6 -Dimethylphenyl)pyridin-2-yl)oxy)methylene)-2,3-dihydrobenzofuran-3-yl)acetic acid (compound HYH-074)
- Example 80 2-(6-((6-(2,6-Dimethyl-4-(2-(piperidin-1-yl)ethoxy)phenyl)pyridin-2-yl)oxy Preparation of methylene)-2,3-dihydrobenzofurazol-3-yl)acetic acid (compound HYH-076)
- Compound 2-(6- was prepared in a similar manner to Example 65 except that 2-(piperidin-1-yl)ethyltoluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester. :(:6-(2,6-Dimethyl-4-(2-(piperidin-1-yl)ethoxy)phenyl)pyridin-2-yl)oxy)methylene)-2,3 -Dihydrobenzofuran-3-yl)acetic acid.
- Compound 2-(6- was prepared in a similar manner to Example 65 except that 2-(piperazin-1-yl)ethyltoluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester. :(:6-(2,6-Dimethyl-4-(2-(piperazin-1-yl)ethoxy)phenyl)pyridin-2-yl)oxy)methylene)-2,3 -Dihydrobenzofuran-3-yl)acetic acid.
- a compound was prepared in a similar manner to Example 65 except that 2-(4-methylpiperazin-1-yl:)ethyltoluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester.
- Step 1 The compound 2-(6-(bromomethyl)-2,3- was obtained in a similar manner to Example 64 except that 3-methylthiobenzyl alcohol was used instead of 3-methoxybenzyl alcohol. Ethyl dihydrobenzothiophen-3-yl).
- Step 2 In addition to 2-(6-(bromomethyl)-2,3-dihydrobenzothiophen-3-yl)acetate, 2-(6-(bromomethyl)-2,3- In the same manner as in Example 65, the compound 2-(6-(2-(2,6-dimethyl-4-(2)) - (Methanesulfonyl)ethoxy)phenyl)pyridin-2-yl)oxy)methylene)-2,3-dihydrobenzothiophen-3-yl)acetic acid.
- a compound 2-(6-:(:6) was obtained in a similar manner to Example 84 except that 3-methanesulfonylpropyl p-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester.
- a compound 2-(6-:(:6) was obtained in a similar manner to Example 84 except that 4-methanesulfonylbutyl p-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester.
- 4-methanesulfonylbutyl p-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester.
- the compound 2-(6-X6-K2- was obtained in a similar manner to Example 84 except that 2-dimethylaminoethyl-p-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester.
- the compound 2-(6-X6-K3- was obtained in a similar manner to Example 84 except that 3-dimethylaminopropyl-p-toluenesulfonyl ester was used instead of 2-methanesulfonylethyl p-toluenesulfonyl ester.
- Example 90 Screening of compounds for agonistic activity of HEK293 cell line stably transfected with human GPR40
- HEK293 cells were transfected into eukaryotic expression vector human GPR40-pCDNA3.1, and a monoclonal cell strain stably expressing human GPR40 was obtained by screening.
- the HEK293 cell line stably transfected with human GPR40 was cultured in a high glucose DMEM medium containing 10% FBS.
- the cells were seeded in 96-well cell culture plates at 25,000 cells per well.
- the Fluo-8 working solution was prepared (Hank's balanced salt solution containing Fluo-82 ⁇ , probenecid 2 mM, tartrazine 1.5 mM, acid red 14 mM).
- Example 91 Hypoglycemic effect of compounds on type II diabetes ob/ob mice
- mice Male genetic type spontaneous type 2 diabetes ob/ob mice were housed in SPF animal rooms (temperature: 22-24 ° C, humidity: 45-80%, light: 150-300 Lx, 12 hours day and night), mice 6-7 weeks old prediction random blood glucose, fasting blood glucose and body weight, based on these indicators will ob / ob mice were divided into 3 groups, 8 per group, were orally administered 100m g / kg of the test compound HYH-013, 100 The mg/kg positive control was TAK875, and the control group was orally administered with 0.5% CMC. The blood glucose level was measured before administration and at 1h, 2h, 4h, 6h and 8h after administration. HYH-013 was observed for type II diabetes ob/ob mice. Hypoglycemic effect.
- the results are shown in Table 2 and Figure 1.
- the blood glucose of the control ob/ob mice was maintained at a high level before and after administration, and single oral administration of 100 mg/kg HYH-013 significantly reduced ob/ob.
- Mouse blood sugar At 1 h after administration, the blood glucose of HYH-013 mice was significantly lower than that of the control group (P ⁇ 0.01), and the blood glucose decline rate was 22.3%.
- the blood glucose of the positive control TAK-875 group did not decrease significantly compared with the control group; 2 h after administration At 4h, the blood glucose of HYH-013 group was significantly lower than that of the control group (PO.05), and the blood glucose decline rate was 26.3% and 23.4%, respectively.
- the blood glucose of HYH-013 group was still significantly lower than that of the control group (P ⁇ 0.05, P ⁇ 0.01), and the blood glucose decreased. The rates were 24.7% and 26.8%, respectively, while the blood glucose of the positive control TAK875 group had no significant decrease compared with the control group. This suggests that HYH-013 has a significant hypoglycemic effect on type 2 diabetic ob/ob mice, and its effect lasts longer than TAK875.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention porte sur un composé de phénylalanine ayant un groupe de liaison hétérocyclique azoté, qui permet d'abaisser considérablement la glycémie et de réguler l'activité métabolique sur les glycolipides, sur ses sels pharmaceutiquement acceptables ou stéréoisomères, sur des compositions pharmaceutiques comprenant le composé et sur l'utilisation du composé en préparation de médicaments pour des troubles diabétiques et du métabolisme des glycolipides, en particulier sur son utilisation en préparation de médicaments pour le traitement du diabète de type II. Le composé a une structure telle que représentée dans la formule I.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310132684.6 | 2013-04-16 | ||
CN201310132684.6A CN104109115B (zh) | 2013-04-16 | 2013-04-16 | 一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014169817A1 true WO2014169817A1 (fr) | 2014-10-23 |
Family
ID=51706126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2014/075466 WO2014169817A1 (fr) | 2013-04-16 | 2014-04-16 | Composé de phénylalanine ayant un groupe de liaison hétérocyclique azoté, composition pharmaceutique associée, son procédé de préparation et son utilisation |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN104109115B (fr) |
WO (1) | WO2014169817A1 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10710986B2 (en) | 2018-02-13 | 2020-07-14 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10774071B2 (en) | 2018-07-13 | 2020-09-15 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US11279702B2 (en) | 2020-05-19 | 2022-03-22 | Kallyope, Inc. | AMPK activators |
US11407768B2 (en) | 2020-06-26 | 2022-08-09 | Kallyope, Inc. | AMPK activators |
US11512065B2 (en) | 2019-10-07 | 2022-11-29 | Kallyope, Inc. | GPR119 agonists |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107556252A (zh) * | 2016-06-30 | 2018-01-09 | 中国科学院上海药物研究所 | 一种含吡嗪环链接的苯丙酸类化合物、其药物组合物、制备方法和用途 |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005080367A1 (fr) * | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Agonistes des recepteurs ep2 |
WO2005095338A1 (fr) * | 2004-03-30 | 2005-10-13 | Takeda Pharmaceutical Company Limited | Dérivés de l’acide alkoxyphénylpropanoïque |
CN1735408A (zh) * | 2002-11-08 | 2006-02-15 | 武田药品工业株式会社 | 受体机能调节剂 |
WO2006127503A2 (fr) * | 2005-05-20 | 2006-11-30 | Amgen Inc | Composes, compositions pharmaceutiques et methodes d'utilisation de ces derniers dans le traitement des troubles du metabolisme |
CN1922165A (zh) * | 2003-12-25 | 2007-02-28 | 武田药品工业株式会社 | 3-(4-苄氧基苯基)丙酸衍生物 |
CN1946666A (zh) * | 2004-02-27 | 2007-04-11 | 埃姆艮股份有限公司 | 用于治疗代谢性疾病的化合物、药物组合物和方法 |
WO2007106469A2 (fr) * | 2006-03-14 | 2007-09-20 | Amgen Inc. | Derives bicycliques de l'acide carboxylique utiles dans le traitement de troubles metaboliques |
WO2008030618A1 (fr) * | 2006-09-07 | 2008-03-13 | Amgen Inc. | Composés benzo-fusionnés destinés à être utilisés dans le traitement de troubles métaboliques |
WO2008130514A1 (fr) * | 2007-04-16 | 2008-10-30 | Amgen Inc. | Modulateurs de gpr40 des acides biphényle phénoxy, thiophényle et aminophénylpropanoïque substitués |
WO2009012650A1 (fr) * | 2007-07-25 | 2009-01-29 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. | Dérivés d'arylpyrimidine, procédés de préparation et utilisations pharmaceutiques de ces dérivés |
CN101411704A (zh) * | 2007-10-15 | 2009-04-22 | 中国科学院上海药物研究所 | 一类嘧啶取代苯丙酸化合物在制备预防和/或治疗糖尿病药物中的用途 |
US20110195993A1 (en) * | 2008-05-26 | 2011-08-11 | Christophe Masson | Ppar agonist compounds, preparation and uses |
CN102307860A (zh) * | 2008-12-18 | 2012-01-04 | 麦它波莱克斯股份有限公司 | Gpr120受体激动剂及其用途 |
CN103030646A (zh) * | 2011-09-29 | 2013-04-10 | 上海恒瑞医药有限公司 | 苯并二氧六环类衍生物、其制备方法及其在医药上的应用 |
-
2013
- 2013-04-16 CN CN201310132684.6A patent/CN104109115B/zh not_active Expired - Fee Related
-
2014
- 2014-04-16 WO PCT/CN2014/075466 patent/WO2014169817A1/fr active Application Filing
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1735408A (zh) * | 2002-11-08 | 2006-02-15 | 武田药品工业株式会社 | 受体机能调节剂 |
CN1922165A (zh) * | 2003-12-25 | 2007-02-28 | 武田药品工业株式会社 | 3-(4-苄氧基苯基)丙酸衍生物 |
WO2005080367A1 (fr) * | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Agonistes des recepteurs ep2 |
CN1946666A (zh) * | 2004-02-27 | 2007-04-11 | 埃姆艮股份有限公司 | 用于治疗代谢性疾病的化合物、药物组合物和方法 |
WO2005095338A1 (fr) * | 2004-03-30 | 2005-10-13 | Takeda Pharmaceutical Company Limited | Dérivés de l’acide alkoxyphénylpropanoïque |
WO2006127503A2 (fr) * | 2005-05-20 | 2006-11-30 | Amgen Inc | Composes, compositions pharmaceutiques et methodes d'utilisation de ces derniers dans le traitement des troubles du metabolisme |
WO2007106469A2 (fr) * | 2006-03-14 | 2007-09-20 | Amgen Inc. | Derives bicycliques de l'acide carboxylique utiles dans le traitement de troubles metaboliques |
WO2008030618A1 (fr) * | 2006-09-07 | 2008-03-13 | Amgen Inc. | Composés benzo-fusionnés destinés à être utilisés dans le traitement de troubles métaboliques |
WO2008130514A1 (fr) * | 2007-04-16 | 2008-10-30 | Amgen Inc. | Modulateurs de gpr40 des acides biphényle phénoxy, thiophényle et aminophénylpropanoïque substitués |
WO2009012650A1 (fr) * | 2007-07-25 | 2009-01-29 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. | Dérivés d'arylpyrimidine, procédés de préparation et utilisations pharmaceutiques de ces dérivés |
CN101411704A (zh) * | 2007-10-15 | 2009-04-22 | 中国科学院上海药物研究所 | 一类嘧啶取代苯丙酸化合物在制备预防和/或治疗糖尿病药物中的用途 |
US20110195993A1 (en) * | 2008-05-26 | 2011-08-11 | Christophe Masson | Ppar agonist compounds, preparation and uses |
CN102307860A (zh) * | 2008-12-18 | 2012-01-04 | 麦它波莱克斯股份有限公司 | Gpr120受体激动剂及其用途 |
CN103030646A (zh) * | 2011-09-29 | 2013-04-10 | 上海恒瑞医药有限公司 | 苯并二氧六环类衍生物、其制备方法及其在医药上的应用 |
Non-Patent Citations (1)
Title |
---|
NEGORO, N. ET AL.: "Identification of Fused-Ring Alkanoic Acids with Improved Pharmacokinetic Profiles that Act as G Protein-Coupled Receptor 40/Free Fatty Acid Receptor I Agonists", JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, no. 4, 16 January 2012 (2012-01-16), pages 1538 - 1552, XP002696495, DOI: doi:10.1021/jm2012968 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10710986B2 (en) | 2018-02-13 | 2020-07-14 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US11555029B2 (en) | 2018-02-13 | 2023-01-17 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10774071B2 (en) | 2018-07-13 | 2020-09-15 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US11512065B2 (en) | 2019-10-07 | 2022-11-29 | Kallyope, Inc. | GPR119 agonists |
US11279702B2 (en) | 2020-05-19 | 2022-03-22 | Kallyope, Inc. | AMPK activators |
US11851429B2 (en) | 2020-05-19 | 2023-12-26 | Kallyope, Inc. | AMPK activators |
US11407768B2 (en) | 2020-06-26 | 2022-08-09 | Kallyope, Inc. | AMPK activators |
Also Published As
Publication number | Publication date |
---|---|
CN104109115A (zh) | 2014-10-22 |
CN104109115B (zh) | 2016-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014169817A1 (fr) | Composé de phénylalanine ayant un groupe de liaison hétérocyclique azoté, composition pharmaceutique associée, son procédé de préparation et son utilisation | |
CN111647000B (zh) | 吡嗪类衍生物及其在抑制shp2中的应用 | |
EP2803664B1 (fr) | Dérivés de tetrahydrobenzofurane en tant qu`agonistes du récepteur gpr40 pour le traiment du diabète | |
CN112601525B (zh) | 2,6-二氨基吡啶化合物 | |
TW200418801A (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
WO2014036897A1 (fr) | Dérivés d'imidazoline, leurs procédés de préparation et leurs applications en médecine | |
FR2787789A1 (fr) | Benzopyranes et benzoxepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparations | |
WO2007114213A1 (fr) | Dérivé cyclique bicyclique substitué et son utilisation | |
KR102005068B1 (ko) | 1,2 나프토퀴논 유도체 및 이의 제조방법 | |
JP5476587B2 (ja) | エストロゲン受容体に対して活性を有する縮合化合物 | |
EP2300424B1 (fr) | Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson | |
US9695181B2 (en) | Hydroximic acid derivatives and medical applications therof | |
KR101644778B1 (ko) | 1,2 나프토퀴논 유도체 및 이의 제조방법 | |
CA2905729C (fr) | Derives pyrroles bicycliques utiles en tant qu'agonistes de gpr120 | |
TW201124401A (en) | New phenoxypyrimidine derivatives | |
CN110903224A (zh) | 一种芳基磺酰胺类化合物、其制备方法、药物组合物及用途 | |
JP2022542613A (ja) | ヒトatglの阻害剤 | |
KR20230078737A (ko) | Fxr 저분자 작용제 및 이의 제조 방법과 용도 | |
JP7177042B2 (ja) | 複素環化合物 | |
CA3178798A1 (fr) | Derives de 3-((1h-pyrazol-4-yl)methyl)-6'-(phenyl)-2h-(1,2'-bipyridin)-2-one et composes apparentes servant d'antagonistes de gpr139 pour une utilisation dans une methode de traitement de la depression, par exempl | |
CN111393421A (zh) | 丁烯酸内酯类衍生物及其制备方法与应用 | |
TWI828783B (zh) | 聯芳基衍生物及其用途 | |
JP7177043B2 (ja) | 複素環化合物 | |
JP2008543741A (ja) | 新規な化合物 | |
US20070191425A1 (en) | Solifenacin-containing composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14784917 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14784917 Country of ref document: EP Kind code of ref document: A1 |